Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains?

Core Viewpoint - Day One Biopharmaceuticals, Inc. (DAWN) experienced a significant stock rally of 26.7% due to strong preliminary sales figures for its drug Ojemda, which is aimed at treating pediatric low-grade glioma [1][2]. Financial Performance - Preliminary net product revenues for Ojemda were approximately $52.8 million for Q4 2025 and $155.4 million for the full year 2025, marking a 172% year-over-year increase [3]. - For full-year 2026, the company anticipates Ojemda net product revenue to be between $225 million and $250 million, indicating a projected 53% year-over-year growth at the midpoint [3]. Earnings Expectations - The company is expected to report a quarterly loss of $0.18 per share, reflecting a year-over-year change of +73.9%, with revenues projected at $43.25 million, up 48.1% from the previous year [4]. - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, suggesting that stock price movements may be influenced by trends in earnings estimate revisions [5]. Industry Context - Day One Biopharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry, where IDEAYA Biosciences, Inc. (IDYA) also operates, having experienced a 1.4% decline in the last trading session [6]. - IDEAYA's consensus EPS estimate for its upcoming report has remained unchanged at -$1.03, representing a +30.9% change from the previous year [7].